Form 4: Aileron Therapeutics Director William Fairey Acquires Stock Options

Director William Fairey of Aileron Therapeutics acquired stock options on August 20, 2024, as reported in a Form 4 filing with the SEC.

Summary

• William Fairey, a director of Aileron Therapeutics, acquired stock options on August 20, 2024.
• The options grant the right to buy 2,725 shares of Aileron Therapeutics common stock at an exercise price of $2.40.
• The options vest in full on the earlier of August 20, 2025, or the date of the Issuer's 2025 Annual Meeting of Stockholders.
• Following the transaction, Fairey directly owns 2,725 derivative securities.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The grant of options could be seen as mildly positive, reflecting confidence in the company, but it's a routine event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It is common for directors and officers of publicly traded companies to receive stock options as part of their compensation.

Stakeholder Impact

• The granting of stock options to a director could potentially align the director's interests with those of the shareholders.

Key Dates